New treatment aims to wipe out lingering leukemia cells
NCT ID NCT07052695
Summary
This study is testing whether the drug mosunetuzumab, given alone or with other leukemia medications, can eliminate tiny amounts of remaining cancer cells in patients with chronic lymphocytic leukemia. The goal is to achieve 'undetectable minimal residual disease' - meaning no detectable cancer cells - which may help control the disease longer. About 40 patients who have already received standard treatments will participate in this early-phase trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham & Women's Hospital
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.